Shandong Weigao Group Medical Polymer Co Ltd
HKEX:1066

Watchlist Manager
Shandong Weigao Group Medical Polymer Co Ltd Logo
Shandong Weigao Group Medical Polymer Co Ltd
HKEX:1066
Watchlist
Price: 4.34 HKD 2.84% Market Closed
Market Cap: 19.8B HKD
Have any thoughts about
Shandong Weigao Group Medical Polymer Co Ltd?
Write Note

Shandong Weigao Group Medical Polymer Co Ltd
PP&E Gross

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Shandong Weigao Group Medical Polymer Co Ltd
PP&E Gross Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Gross CAGR 3Y CAGR 5Y CAGR 10Y
Shandong Weigao Group Medical Polymer Co Ltd
HKEX:1066
PP&E Gross
ÂĄ7.3B
CAGR 3-Years
5%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Eyebright Medical Technology Beijing Co Ltd
SSE:688050
PP&E Gross
ÂĄ1.4B
CAGR 3-Years
70%
CAGR 5-Years
59%
CAGR 10-Years
N/A
S
Shandong Pharmaceutical Glass Co Ltd
SSE:600529
PP&E Gross
ÂĄ3.6B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Autobio Diagnostics Co Ltd
SSE:603658
PP&E Gross
ÂĄ4.1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Winner Medical Co Ltd
SZSE:300888
PP&E Gross
ÂĄ4.2B
CAGR 3-Years
41%
CAGR 5-Years
20%
CAGR 10-Years
N/A
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
PP&E Gross
ÂĄ1.4B
CAGR 3-Years
19%
CAGR 5-Years
15%
CAGR 10-Years
N/A
No Stocks Found

Shandong Weigao Group Medical Polymer Co Ltd
Glance View

Market Cap
19.8B HKD
Industry
Health Care

Nestled in the bustling industrial heart of China, Shandong Weigao Group Medical Polymer Co Ltd stands as a testament to the transformative potential within the field of medical devices. Since its inception in 1988, Weigao has diligently carved out a niche within the healthcare sector, specializing in the production and distribution of medical consumables, orthopedic materials, and blood purification apparatus. The company's journey is intertwined with China's healthcare evolution, as it became a critical player in supplying hospitals and medical institutions with essential, reliable tools. By leveraging advancements in polymer science, Weigao consistently pushes the boundaries in creating high-quality, cost-effective products—a maneuver that not only reduces healthcare costs but also ensures widespread accessibility to essential medical supplies. Driven by an intricate understanding of the medical landscape, Weigao's operational model hinges on its robust vertical integration strategy. The company effectively controls every stage of its production process, from raw material procurement to product manufacturing and distribution. This control not only ensures stringent quality checks but also allows for improved economies of scale, thereby boosting its profitability margins. Revenue streams largely stem from its extensive product lineup, which includes syringes, blood bags, infusion sets, and orthopedic devices, catering to domestic demand while also penetrating international markets. The constant stream of innovations, coupled with an expanding global footprint, underscores Weigao's commitment to growth, firmly positioning it as a stalwart in the medical apparatus industry.

Intrinsic Value
8.37 HKD
Undervaluation 48%
Intrinsic Value
Price

See Also

What is Shandong Weigao Group Medical Polymer Co Ltd's PP&E Gross?
PP&E Gross
7.3B CNY

Based on the financial report for Jun 30, 2024, Shandong Weigao Group Medical Polymer Co Ltd's PP&E Gross amounts to 7.3B CNY.

What is Shandong Weigao Group Medical Polymer Co Ltd's PP&E Gross growth rate?
PP&E Gross CAGR 5Y
6%

Over the last year, the PP&E Gross growth was 0%. The average annual PP&E Gross growth rates for Shandong Weigao Group Medical Polymer Co Ltd have been 5% over the past three years , 6% over the past five years .

Back to Top